Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients

Journal of the American Society of Nephrology

Volumn 11, Issue 12, 2000, Pages 2366-2370

  Meier Kriesche, Herwig Ulf ^a   Ojo, Akinlolu O ^a   Leichtman, Alan B ^a   Punch, Jeffrey D ^a   Hanson, Julie A ^a   Cibrik, Diane M ^a   Kaplan, Bruce ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; CAUCASIAN; DRUG EFFICACY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 0033663061     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345: 1321-1325, 1995
2. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61: 1029-1037, 1996
3. European Mycophenolate Mofetil Cooperative Study Group: Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 68: 391-396, 1999
4. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cibrik D, Magee JC, Wolfe RA, Agodoa LY, Kaplan B: Mycophenolate mofetil reduces chronic renal allograft loss independent of acute rejection. Transplantation 69: 2405-2409, 2000
5. Neylan JF: Immunosuppressive therapy in high-risk transplant patients: Dose- dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 64: 1277-1282, 1997
6. Katznelson S, Gjertson DW, Cecka JM: The effect of race and ethnicity on kidney allograft outcome. Clin Transpl 379-394, 1995
7. Zhou YC, Cecka JM, Terasaki PI: Effect of race on kidney transplants. Clin Transpl 447-459, 1990
8. Yuge J, Cecka JM: The race effect. Clin Transpl 407-416, 1989
9. Barger BO, Hudson SL, Shroyer TW, Deierhoi MH, Barber WH, Curtis JT, Julian BA, Luke RG, Diethelm AG: Influence of race on renal allograft survival in the pre- and postcyclosporine era. Clin Transpl 217-233, 1987
10. Chertow GM, Milford EL: Poorer graft survival in African-American transplant recipients cannot be explained by HLA mismatching. Adv Ren Replace Ther 4: 40-45, 1997
11. Neylan JF: Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine: FK506 Kidney Transplant Study Group. Transplantation 65: 515-523, 1998
12. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J: Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trial. Rapamune Study Group. Transplantation 68: 1526-1532, 1999
13. Schweitzer EJ, Yoon S, Fink J, Wiland A, Anderson L, Kuo PC, Lim JW, Johnson LB, Farney AC, Weir MR, Bartlett ST: Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients. Transplantation 65: 242-248, 1998 MzquAU: Please spell out AB & DR.